The CEMI trial included a notable proportion of unresectable locally advanced NSCLC patients who were not candidates for definitive chemoradiation (15% in the PD-L1 ≥50% population and 16% in the intention-to-treat population) [18]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.